Accepted for Publication: December 20, 2021.
Published Online: January 7, 2022. doi:10.1001/jama.2021.24355
Corresponding Author: Joshua S. Gans, PhD, Rotman School of Management, University of Toronto, 105 St George St, Toronto, ON M5S3E6, Canada (joshua.gans@utoronto.ca).
Author Contributions: Drs Goldfarb and Rosella had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Goldfarb, Agrawal, Sennik, Stein, Rosella.
Acquisition, analysis, or interpretation of data: Gans, Goldfarb, Agrawal, Sennik, Rosella.
Drafting of the manuscript: Gans, Goldfarb.
Critical revision of the manuscript for important intellectual content: Goldfarb, Agrawal, Sennik, Stein, Rosella.
Statistical analysis: Goldfarb, Rosella.
Obtained funding: Agrawal, Sennik, Stein.
Administrative, technical, or material support: Gans, Goldfarb, Agrawal, Sennik.
Supervision: Agrawal, Sennik.
Conflict of Interest Disclosures: All authors are members of the Steering Committee of the Creative Destruction Lab Rapid Screening Consortium (CDL RSC; a nonprofit organization in Canada). Dr Agrawal reported serving on the boards of Genpact and Sanctuary.
Funding/Support: The CDL RSC was founded with financial support from 12 corporations: Air Canada, CPP Investments, Genpact, Loblaw Companies Limited, Magna, MDA, Maple Leafs Sports & Entertainment Partnership, Nutrien, Rogers, Scotiabank, Shoppers Drug Mart, and Suncor and received funding from the Safe Restart Agreement from the Government of Canada (Health Canada).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank Kyle Robinson, PhD, Devon Elke, HBSc, and Evgenia Gatov, MPH (all paid employees of CDL RSC, Toronto, Ontario, Canada), for assistance in collating the data.
1.Kretschmer
A , Kossow
A , Grüne
B , Schildgen
O , Mathes
T , Schildgen
V . False positive rapid antigen tests for SARS-CoV-2 in the real-world and their economic burden.
J Infect. Published online August 17, 2021. doi:
10.1016/j.jinf.2021.08.020PubMedGoogle Scholar 3.Kanji
JN , Proctor
DT , Stokes
W ,
et al. Multicenter postimplementation assessment of the positive predictive value of SARS-CoV-2 antigen-based point-of-care tests used for screening of asymptomatic continuing care staff.
J Clin Microbiol. 2021;59(11):e0141121. doi:
10.1128/JCM.01411-21
PubMedGoogle Scholar